Literature DB >> 23143928

Novel insights into phosgene-induced acute lung injury in rats: role of dysregulated cardiopulmonary reflexes and nitric oxide in lung edema pathogenesis.

Wenli Li1, Fangfang Liu, Chen Wang, Hubert Truebel, Juergen Pauluhn.   

Abstract

Phosgene gas is a lower respiratory tract irritant. As such, it stimulates nociceptive vagal C-fiber-related reflexes in a dose-rate and concentration × exposure duration (C × t)-dependent manner. In rats, this reflex is characterized by extended apnea time periods, bradycardia, and hypothermia. Although inhalation exposures at nonlethal C × t products show rapid reversibility of reflexively induced changes in respiratory patterns, lethal C × t products seem to cause prolonged stimulation after discontinued exposure to phosgene. This observation has been taken as indirect evidence that phosgene-induced lethal lung edema is likely to be associated with a dysfunctional neurogenic control of cardiopulmonary and microvascular physiology. In order to verify this hypothesis, data from respiratory function measurements during and after the inhalation exposure to phosgene gas were compared with time-course measurements of cardiac function over 20 h post-phosgene exposure. These data were complemented by time-course analyses of nitric oxide (NO(e)) and carbon dioxide in exhaled breath, including time-dependent changes of extravasated protein in bronchoalveolar lavage fluid and hemoglobin in blood. The nitric oxidase synthetase inhibitors L-NAME and L-NIL were used to further elucidate the role of NO(e) in this type of acute lung injury and whether its analysis can serve as an early biomarker of pulmonary injury. Collectively, the sequence and time course of pathological events in phosgene-induced lung edema appear to suggest that overstimulated, continued sensorimotor vagal reflexes affect cardiopulmonary hemodynamics. A continued parasympathetic tone appears to be involved in this etiopathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143928     DOI: 10.1093/toxsci/kfs317

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  7 in total

1.  NOS-2 Inhibition in Phosgene-Induced Acute Lung Injury.

Authors:  Piotr T Filipczak; Albert P Senft; JeanClare Seagrave; Waylon Weber; Philip J Kuehl; Laura E Fredenburgh; Jacob D McDonald; Rebecca M Baron
Journal:  Toxicol Sci       Date:  2015-04-13       Impact factor: 4.849

2.  Conceptual approaches for treatment of phosgene inhalation-induced lung injury.

Authors:  Wesley W Holmes; Brian M Keyser; Danielle C Paradiso; Radharaman Ray; Devon K Andres; Betty J Benton; Cristin C Rothwell; Heidi M Hoard-Fruchey; James F Dillman; Alfred M Sciuto; Dana R Anderson
Journal:  Toxicol Lett       Date:  2015-11-10       Impact factor: 4.372

3.  Characterization of a nose-only inhaled phosgene acute lung injury mouse model.

Authors:  Jennifer L Plahovinsak; Mark R Perry; Katherine A Knostman; Robert Segal; Michael C Babin
Journal:  Inhal Toxicol       Date:  2015       Impact factor: 2.724

Review 4.  Phosgene-induced acute lung injury (ALI): differences from chlorine-induced ALI and attempts to translate toxicology to clinical medicine.

Authors:  Wenli Li; Juergen Pauluhn
Journal:  Clin Transl Med       Date:  2017-06-02

Review 5.  Mechanism of Phosgene-Induced Acute Lung Injury and Treatment Strategy.

Authors:  Qianying Lu; Siyu Huang; Xiangyan Meng; Jianfeng Zhang; Sifan Yu; Junfeng Li; Mingyu Shi; Haojun Fan; Yanmei Zhao
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

6.  An amino-substituted 2-(2'-hydroxyphenyl)benzimidazole for the fluorescent detection of phosgene based on an ESIPT mechanism.

Authors:  Zi-Jie Li; Wen-Jie Zhang; Wen-Zhu Bi; Qiu-Juan Ma; Su-Xiang Feng; Xiao-Lan Chen; Ling-Bo Qu
Journal:  RSC Adv       Date:  2021-03-15       Impact factor: 3.361

7.  Phosgene-Induced acute lung injury: Approaches for mechanism-based treatment strategies.

Authors:  Chao Cao; Lin Zhang; Jie Shen
Journal:  Front Immunol       Date:  2022-08-02       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.